Aller au contenu principal
Accès ouvert déclaré 2025 article

Characterization of ITIH6, a novel inter-α-inhibitor family member with prognostic significance in cholangiocarcinoma

1Citations signalées — pas une note de qualité
8Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

The family of inter-α-trypsin inhibitors (ITI) includes proteins with a conserved light chain and a variable number of heavy chains. Here, we present the first characterization of ITIH6, a previously uncharacterized member of the ITI heavy chain (ITIH) family, using different bioinformatics analysis tools. ITIH6 contains the two canonical domains characteristic of ITIH proteins (VIT, vWA), but also harbors a large central region between the vWA domain and the C-terminus that is unique to ITIH6. Phylogenetic analysis further revealed that ITIH6 is most closely related to ITIH5, forming a separate subfamily. Protein expression profiling of human tissue samples demonstrated that ITIH6 is expressed in a tissue-specific manner, with abundant expression in salivary glands, kidney, colon, and stomach, particularly within glandular structures of the digestive tract. Extending our previous findings on the clinical relevance of ITIH5 in cholangiocarcinoma (CCA), we identified an overlapping yet distinct expression pattern of ITIH6 in CCA. Importantly, elevated ITIH6 expression correlates with favorable prognosis and was more pronounced in tumors with single lesions, suggesting its potential utility as a prognostic biomarker in CCA. Taken together, these findings highlight the unique structural and functional features of ITIH6 and emphasize its potential clinical significance in cancer biology.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Characterization of ITIH6, a novel inter-α-inhibitor family member with prognostic significance in cholangiocarcinoma
Date Crossref
01/11/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Cholangiocarcinoma and Gallbladder Cancer StudiesPeptidase Inhibition and AnalysisCancer Mechanisms and Therapy

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.